90%Confidence
0Views
FDASource
2026-03-23Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance issues creates significant safety concerns for this popular diabetes/weight loss medication. This could disrupt supply and damage brand reputation in a highly competitive GLP-1 receptor agonist market, potentially benefiting established manufacturers like Novo Nordisk and Eli Lilly.
Actionable: Evaluate exposure to New Life Pharma and consider opportunities in competing semaglutide manufacturers who may capture market share from this recall.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now